Since 2008, Feiqi has cooperated with Lizhu to build a group LIMS project. At present, it has launched several branches, including the general plant, Limin, Fuxing, Everbright, trial drug and other plants, and established a group integrated quality control platform. After the system was launched, it has met the inspection of GMP, eugmp, wnho and other audit institutions for many times, and passed the group multi organization, It realizes the unified management of MAH licensee on the quality of subordinate agent processing enterprises
Lizhu has made continuous breakthroughs in the fields of API, chemical medicine, traditional Chinese medicine, biological medicine and in vitro diagnostic reagents. Its products are distributed in the fields of digestion, cardio cerebrovascular, reproductive endocrine, spirit / nerve and so on. The company continued to focus on the main business of innovative drugs and complex preparations with high barriers, launched heavy products such as leuprorelin and iprazole, and achieved large-scale growth in the field of digestion and reproduction.
In 2018, the EU certification of Lizhu General Factory conducted an on-site audit on the LMS system of flying enterprises. Eugmp prosecutors, Lizhu pharmaceutical factory executives and quality related personnel and Li mengke, general manager of Yaodian technology attended the meeting.
